chemical:semaglutide
Semaglutide removed from shortage list
It happened sooner than we expected -- the FDA has announced Semaglutide shortage resolution, removing it from the shortage list.
category:news
country:mexico
Mexico and GLP1s
We explore GLP1 medical tourism, supply issues, and adoption of generic GLP1 Receptor Agonists in Mexico.
category:news
Ozempic approved for Chronic Kidney Disease
The FDA has approved Semaglutide for chronic kidney disease. We explore research and the possible implications for insurance coverage and more.
company:novo-nordisk
Novo's Amycretin delivers great Phase 2 results
Novo Nordisk's Amycretin produces stellar results in Phase 2 trials -- we dive into Amycretin and other new drugs to see how it compares.
category:news
The battle for compounded GLP1 continues
The battle for compounded GLP1s rages on -- powerful organizations with profit incentives continue to push for compounded GLP1s, with consumers caught in the middle.
government
Government Price negotiations on Ozempic and Wegovy
The government has selected Ozempic and Wegovy for price negotiations -- are we going to see cheaper prices?
category:side-effects
Pancreatitis and Gallstones after massive weight loss
We look into pancreatitis and gallstones issues that caused one death and more hospitalizations, caused at least in part by GLP1s
category:news
Robert F. Kennedy Jr vs GLP1
RFK Jr.'s appointment and it's effect on GLP1s. Is it truly anti-GLP1? Or a case of tactics?
research
Research suggesting GLP1 is a brain drug
Why has modern scientific opinion shifted to GLP1 being a brain drug rather than a gut drug? We dive into the critical research paper supporting the shift.
company:hikma
Another Generic Liraglutide launch: Hikma Phamaceuticals
A new player enters the generic GLP1 market - Hikma Pharmaceuticals. As the second generic Liraglutide provider, accessibility of GLP1s has never been better.
category:news
HIMS to offer Liraglutide after shortage rule changes
HIMS leans into Liraglutide as a replacement for Semaglutide in the face of shortage rule changes. Is it good enough?
company:eli-lilly
Eli Lilly brands GLP1s as "anti-hedonics"
Eli Lilly leans into the use of GLP1s for reducing addictive behavior, labeling them "anti-hedonics"